Transcatheter aortic valve replacement: History and current status |
| |
| Authors: | Erin A. Bohula May David Faxon |
| |
| Affiliation: | 1. Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand;2. Experimental Cardiovascular Medicine, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Upper Maudlin Street, Bristol BS2 8HW, UK;1. Inserm CIC 007, centre d’investigation clinique, hôpital Bichat–Claude-Bernard, 46, rue Henri-Huchard, 75877 Paris cedex 18, France;2. University Paris Diderot, Sorbonne Paris Cité, UMR 738, 75018 Paris, France;1. Office of Safety and Medical Operations, The Children''s Hospital of Philadelphia, Philadelphia, Pennsylvania;2. The Cardiac Center, The Children''s Hospital of Philadelphia, Philadelphia, Pennsylvania;3. Department of Anesthesia and Critical Care Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania |
| |
| Abstract: | Despite the poor prognosis associated with severe, symptomatic aortic stenosis, treatment options were limited for a large subgroup of patients deemed high risk for surgical replacement. The introduction of transcatheter aortic valve replacement (TAVR) over the past 10 years marks a new and exciting era in the treatment of valvular disease in these high-risk and inoperable patients. In this review, we outline the historical development, key clinical trials, current outcomes and future directions of TAVR. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
